Sep 8 2014
Mediomics, LLC has been awarded a $969,770 Phase II SBIR contract (HHSN261201300047C) from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services.
After successful completion of Phase I research, this project aims to develop a panel of high affinity scFvs for the detection of O-GlcNAc modified proteins. Using Mediomics’ innovative molecular PINCER® platform, Mediomics will develop the most effective methods to quickly screen for high affinity monoclonal antibodies to detect important post-translation modifications of proteins.
Mediomics provides innovative assay kits, biosensors, and multiplexed assays for academic and corporate research, point of care testing, food and pharmaceutical production process control, as well as the medical and environmental research markets. These assay kits will be used to quantify most biologically and therapeutically important macromolecules, including ligands, proteins, protein complexes, and pathogens, including bacteria, fungi, and viruses. The in vitro diagnostics market is expected to reach $74.46 billion by 2020, which demonstrates a steady growth from an anticipated value of $69.1 billion in 2017 and its estimated value of $51 billion in 2010.
The company’s rapid, mix-and–measure homogeneous assays have already been adapted for the detection of a range of biologically and therapeutically important macromolecules, including cAMP, tryptophan, S-adenosyl methionine, L-Methionine, PDE, biotin, human insulin, human albumin, human C-reactive protein (hCRP), IgG, IgM, E. coli, and others.
In addition, Mediomics has also received an SBIR Phase II contract (200-2012-52857) from the CDC to develop robust and cost-effective homogeneous assays for quick detection of HCV infection, and an SBIR Phase II contract (HHSN261201200081C) from National Cancer Institute to develop a fully automated in-process bioanalyzer to detect the titer of protein drugs during their production.
About Mediomics, LLC:
Mediomics is a St. Louis based Biotech company. The Company is commercializing core technologies for which it has secured an exclusive license from Saint Louis University, including the following: (i) a DNA-binding protein-based bioassay, biosensor, multiplexed platform, (ii) a related variant – the molecular PINCER®-based homogeneous biosensor, bioassay, multiplexed assay platforms and companion devices, and (iii) innovative, proprietary methods to screen and develop new high-affinity capture reagents for research, diagnostic, and therapeutic use.
Source: http://www.mediomics.com/